SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY
SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY
复制标题
DOI：
10.1097/iae.0000000000001763
复制
发表时间：
2018-08-01
影响因子：
3.3
通讯作者：
Zhao, Mingwei
中科院分区：
文献类型：
--
作者：
Jin, Enzhong;Yin, Hong;Zhao, Mingwei
目的：玻璃体内注射康柏西普（IVC）是治疗早产儿视网膜病变（ROP）的最新方法。比较IVC或玻璃体内注射雷珠单抗（IVR）治疗ROP患者的结构结局和复发情况。方法：回顾性研究IVC或IVR治疗ROP的连续病例系列。主要结局是治疗成功，定义为+疾病的消退。次要结果为复发率、注射次数和最终疾病消退。结果：共纳入24例（48眼）ROP患者。IVC组10例（20眼），IVR组14例（28眼）。IVC组中18只眼为II区3+ ROP，2只眼为侵袭性后房型ROP。行IVR治疗的28只眼中，Ⅰ区2/3+ ROP 6只眼，侵袭性后区ROP 6只眼，Ⅱ区3+ ROP 16只眼。对于IVC组，婴儿的平均胎龄、出生体重、初始治疗时的经后年龄和随访期分别为29.49 +/- 1.37周、1，369.0 +/- 161.9 g、38.47 +/- 2.72周和52.6 +/- 21.4周。对于接受IVR的婴儿，这些分别为28.35 +/- 1.62周，1，171.4 +/- 279.9 g，38.53 +/- 3.54周和42.9 +/- 9.8周。对于IVC组，20只眼中有17只（85%）只接受了一次注射，并且在4.3 +/-2.08周后发生了疾病的消退。3眼（15%）一次注射未愈合，接受了第二次IVC，并且在3周内出现了疾病的消退。对于IVR组，15/28（53.6%）只眼接受了第二次IVR。其中10眼复发，5眼一次注射未痊愈。结论：康柏西普和雷珠单抗均为治疗ROP的有效药物。Conbercept是一种有效的治疗ROP的新策略，为眼科医生提供了一种新的治疗选择。
Purpose: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared.Methods: A consecutive case series of ROP treated with IVC or IVR were retrospectively studied. The primary outcome was treatment success defined as regression of plus disease. The secondary outcomes were recurrence of plus, times of injection, and the final regression of disease.Results: A total of 48 eyes (24 patients) with ROP were included. Twenty eyes (10 patients) received IVC, and 28 eyes (14 patients) received IVR. For the IVC group, 18 eyes had Zone II 3+ ROP and 2 eyes had aggressive posterior ROP. Among the 28 eyes treated with IVR, 6 eyes had Zone I 2/3+ ROP, 6 eyes had aggressive posterior ROP, and 16 eyes had Zone II 3+ ROP. For the IVC group, the mean gestational age, birth weight, postmenstrual age at initial treatment, and follow-up period for the infants were 29.49 +/- 1.37 weeks, 1,369.0 +/- 161.9 g, 38.47 +/- 2.72 weeks, and 52.6 +/- 21.4 weeks, respectively. And for the infants who received IVR, these were 28.35 +/- 1.62 weeks, 1,171.4 +/- 279.9 g, 38.53 +/- 3.54 weeks, and 42.9 +/- 9.8 weeks, respectively. For the IVC group, 17 (85%) of 20 eyes received the injection only once, and the regression of plus disease occurred 4.3 +/- 2.08 weeks later. Three eyes (15%) did not healed with one injection received a second IVC, and the regression of plus disease occurred within 3 weeks. For the IVR group, 15/28 (53.6%) eyes received a second IVR. Among them, 10 recurrent eyes and 5 eyes did not recover with one injection. No retinal detachment was observed in both group infants.Conclusion: Both conbercept and ranibizumab are effective choice for the treatment of ROP. Conbercept is a novel effective treatment strategy for ROP providing a new treatment option for ophthalmologists.